Myriad Genetics (MYGN) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Myriad Genetics is the larger company by market cap ($412.2 million vs $5.6 million), about 74.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | TRIB |
|---|---|---|
| Share price | $4.31 | $6.86 |
| Market cap | $412.25M | $5.57M |
| 1-day change | +2.62% | +13.49% |
| YTD return | -29.92% | — |
| 1-year return | -44.32% | — |
| 5-year return | -86.42% | — |
| EPS (TTM) | $-1.22 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.59 | $52.50 |
| 52-week low | $2.74 | $5.01 |
| Distance from 52-week high | -49.83% | -86.94% |
| Analyst consensus | hold | — |
| Avg. price target upside | -9.28% | — |
| Average volume | 2.04M | 21.80K |
| Shares outstanding | 95.65M | 813.13K |
| Employees | 2,700 | 287 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 74.0 times larger than Trinity Biotech by market value ($412.25M vs $5.57M).
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees
MYGN vs TRIB FAQ
Which is bigger, Myriad Genetics or Trinity Biotech?
Myriad Genetics (MYGN) is larger, with a market capitalization of $412.25M compared with $5.57M for Trinity Biotech (TRIB).
Are Myriad Genetics and Trinity Biotech in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.